Chemotherapy only for localized Hodgkin lymphoma

Area of Science:

• Oncology
• Radiation Oncology
• Clinical Trials

Background:

• Radiation therapy (RT) has been a primary curative treatment for early-stage Hodgkin lymphoma (HL) for decades.
• Combined modality therapy (CMT), incorporating RT and chemotherapy, is a standard approach.
• Growing concerns regarding long-term side effects of RT have prompted treatment modifications.

Purpose of the Study:

• To evaluate the efficacy of chemotherapy-only regimens for localized Hodgkin lymphoma.
• To identify patient subgroups at higher risk of recurrence who may benefit from limited RT.
• To refine treatment strategies for early-stage HL by balancing efficacy and late toxicity.

Main Methods:

• Review of historical treatment data for Hodgkin lymphoma.
• Analysis of outcomes from clinical trials investigating chemotherapy-only approaches.
• Stratification of patients based on risk factors for recurrence.
• Investigation of limited RT application in specific patient cohorts.

Main Results:

• Chemotherapy alone is a viable treatment option for a majority of patients with localized HL.
• Ongoing clinical trials are identifying high-risk patient subgroups.
• Limited RT may be beneficial when added to chemotherapy for select patients with increased recurrence risk.

Conclusions:

• Treatment strategies for early-stage Hodgkin lymphoma are evolving to minimize long-term morbidity.
• Chemotherapy-based treatments are increasingly effective, reducing the need for extensive RT.
• Personalized treatment approaches, including risk-adapted RT, are crucial for optimizing outcomes in HL.